News stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a news impact score of 0.03 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.1744831732273 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Dicerna Pharmaceuticals (DRNA) traded down $0.50 during midday trading on Wednesday, reaching $8.40. 253,900 shares of the company’s stock traded hands, compared to its average volume of 176,432. Dicerna Pharmaceuticals has a fifty-two week low of $2.42 and a fifty-two week high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The firm had revenue of $0.47 million during the quarter. During the same quarter in the prior year, the company earned ($0.68) earnings per share. The company’s revenue was up 192.6% on a year-over-year basis. sell-side analysts anticipate that Dicerna Pharmaceuticals will post -3.04 EPS for the current fiscal year.

Several equities analysts have issued reports on DRNA shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target (up from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Monday, October 23rd. ValuEngine raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Chardan Capital reaffirmed a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $6.81.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dicerna Pharmaceuticals (DRNA) Share Price” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.